(Last updated : 2022-05-24 13:43:22)
  Yoshiyuki Yamaguchi
   Department     ,
   Position   Professor
■ Present specialized field
Digestive surgery, Immunology, Pathological biochemistry 
■ BooK
1. 2016/03   Overview of Current Cancer Immunotherapy, Immunotherapy of Cancer -- An Innovative Treatment Comes of Age 
2. 2011/03   Adoptive Immunotherapy of Cancer Using Autologous Lymphocytes, Cancer Growth and Progression 
■ Journal
1. 2017/03 Evaluation of pancreatic cancer cell migration with multiple parameters in vitro by using an optical real-time cell mobility assay device  Link
2. 2016/06 Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6- Bmab) versus combination CapeOX/ mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study 
3. 2016/05 A Prospective Observational Study of Adoptive Immunotherapy for Cancer Using Zoledronate-Activated Killer (ZAK) Cells - An Analysis for Patients with Incurable Pancreatic Cancer. 
4. 2015/12 2015 Guidance on cancer immunotherapy development in early-phase clinical studies 
5. 2015/10 Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells 
Display all(58)
■ Presentation
1. 2022/02/17 A Phase III trial of sequential versus combination in metastatic colorectal cancer: C-Cubed study  
2. 2022/02/17 Fluctuating PD-1 ratio in blood may predict clinical outcome of upper gastrointestinal cancer patients under ICI therapy  
3. 2022/01/21 A randomized phase 3 study of sequential versus combination treatment in first-line chemotherapy for metastatic colorectal cancer: The C-cubed study  
4. 2020/10/01 HSP90 inhibition suppresses not only cell proliferation but also chemotaxis in esophageal squamous cell carcinoma  
5. 2019/09/29 Randomized phase III study of sequential treatment with capecitabine or 5-fluorouracil (FP) plus bevacizumab (BEV) followed by the addition with oxaliplatin (OX) versus initial combination with OX+FP+ BEV in the first-line chemotherapy for metastatic colorectal cancer: The C-cubed study  
Display all(34)